Nondisclosure of HIV status in a clinical trial setting: Antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infection

Mark A. Marzinke, William Clarke, Lei Wang, Vanessa Cummings, Ting Yuan Liu, Estelle Piwowar-Manning, Autumn Breaud, Sam Griffith, Susan Buchbinder, Steven Shoptaw, Carlos Del Rio, Manya Magnus, Sharon Mannheimer, Sheldon D. Fields, Kenneth H. Mayer, Darrell P. Wheeler, Beryl A. Koblin, Susan H. Eshleman, Jessica M. Fogel

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

In The HIV Prevention Trials Network 061 study, 155 human immunodeficiency virus (HIV)-infected men reported no prior HIV diagnosis; 83 of those men had HIV RNA levels of <1000 copies/mL at enrollment. Antiretroviral drug testing revealed that 65 of the 83 (78.3%) men were on antiretroviral treatment. Antiretroviral drug testing can help distinguish between newly diagnosed and previously diagnosed HIV infection.

Original languageEnglish (US)
Pages (from-to)117-120
Number of pages4
JournalClinical Infectious Diseases
Volume58
Issue number1
DOIs
StatePublished - Jan 1 2014

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Nondisclosure of HIV status in a clinical trial setting: Antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infection'. Together they form a unique fingerprint.

Cite this